We are live on ! Find out more
LYEL icon

Lyell Immunopharma
LYEL

118 hedge funds and large institutions have $256M invested in Lyell Immunopharma in 2023 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 33 increasing their positions, 30 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

92% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 13

42% more capital invested

Capital invested by funds: $180M → $256M (+$76.2M)

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

11% more funds holding

Funds holding: 106 → 118 (+12)

10% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 30

0.18% more ownership

Funds ownership: 2.44% → 2.62% (+0.18%)

0% more call options, than puts

Call options by funds: $3K | Put options by funds: $3K

Holders
118
Holders Change
+12
Holders Change %
+11.32%
% of All Funds
1.72%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.06%
New
25
Increased
33
Reduced
30
Closed
13
Calls
$3K
Puts
$3K
Net Calls
–
Net Calls Change
-$11K

Top Buyers

1
Citadel Advisors
Citadel Advisors
Florida
+$4.92M
2
Bank of America
Bank of America
North Carolina
+$1.68M
3
BlackRock
BlackRock
New York
+$1.59M
4
Morgan Stanley
Morgan Stanley
New York
+$1.51M
5
ICM
Invenomic Capital Management
Massachusetts
+$1.34M

Top Sellers

1
Vanguard Group
Vanguard Group
Pennsylvania
-$5.95M
2
State Street
State Street
Massachusetts
-$5.89M
3
FCMI
Foresite Capital Management IV
California
-$828K
4
Rafferty Asset Management
Rafferty Asset Management
New York
-$625K
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$478K
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Advisers
101
Two Sigma Advisers
New York
$29.9K +$27.7K +770 New
Federated Hermes
102
Federated Hermes
Pennsylvania
$29.7K +$4.36K +121 +19%
AIM
103
Aigen Investment Management
New York
$29.6K +$2.16K +60 +9%
VF
104
Virtu Financial
New York
$29K +$27.3K +759 New
Dimensional Fund Advisors
105
Dimensional Fund Advisors
Texas
$26.1K – – –
PAS
106
Point72 Asia (Singapore)
Singapore
$25.2K +$23.4K +650 New
Lazard Asset Management
107
Lazard Asset Management
New York
$23K +$11.7K +325 +110%
Mackenzie Financial
108
Mackenzie Financial
Ontario, Canada
$21.7K – – –
X
109
Xponance
Pennsylvania
$19.9K – – –
Qube Research & Technologies (QRT)
110
Qube Research & Technologies (QRT)
United Kingdom
$16.5K +$15.3K +425 New
BMC
111
Bear Mountain Capital
Washington
$12.9K +$11K +305 New
MLICM
112
Metropolitan Life Insurance Company (MetLife)
New York
$12.3K -$6.3K -175 -36%
SO
113
STRS Ohio
Ohio
$10K – – –
Daiwa Securities Group
114
Daiwa Securities Group
Japan
$2K – – –
Nisa Investment Advisors
115
Nisa Investment Advisors
Missouri
$297 +$288 +8 New
FFA
116
Farther Finance Advisors
California
$2 – – –
Rafferty Asset Management
117
Rafferty Asset Management
New York
– -$625K -21,244 Closed
Jacobs Levy Equity Management
118
Jacobs Levy Equity Management
New Jersey
– -$478K -16,268 Closed
PA
119
Profund Advisors
Maryland
– -$108K -3,672 Closed
Ameriprise
120
Ameriprise
Minnesota
– -$66.1K -2,247 Closed
Verition Fund Management
121
Verition Fund Management
Connecticut
– -$51.5K -1,750 Closed
GCP
122
GSA Capital Partners
United Kingdom
– -$51K -1,727 Closed
Ohio Public Employees Retirement System (OPERS)
123
Ohio Public Employees Retirement System (OPERS)
Ohio
– -$40K -1,360 Closed
EFM
124
E Fund Management
China
– -$32K -1,091 Closed
CC
125
Centiva Capital
New York
– -$28.6K -973 Closed
2 3 4
5
6

LYEL Hedge Fund Activity: Q4 2023 in Review

118 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Lyell Immunopharma (LYEL) for Q4 2023, worth a combined $256M — up 42% from $180M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new LYEL positions and 13 closed out — a net gain of 12 holders — while 33 added to existing stakes and 30 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $4.92M. The largest seller was Vanguard Group, cutting an estimated $5.95M.

  • 118 institutional investors held Lyell Immunopharma (LYEL) as of Q4 2023, up from 106 in Q3 2023.
  • Funds reported $256M of Lyell Immunopharma stock for Q4 2023, up 42% quarter-over-quarter.
  • 25 funds opened new Lyell Immunopharma positions in Q4 2023 and 13 closed out, a net change of +12 holders.
  • The largest Lyell Immunopharma buyer in Q4 2023 was Citadel Advisors, an estimated $4.92M added.
  • The largest Lyell Immunopharma seller in Q4 2023 was Vanguard Group, an estimated $5.95M sold.

Based on aggregated 13F filings for Q4 2023.